PROM1 and glioblastoma: That there was no overall survival difference between CD44-M and CD133-M patients in Agilent and Rembrandt datasets is not unexpected as G-CIMP samples aside, there is no long-term difference in survival for the 4 major molecular subtypes of GBM [5].